These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 25287751)

  • 21. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
    Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
    Mashayekhi M; Beckman JA; Nian H; Garner EM; Mayfield D; Devin JK; Koethe JR; Brown JD; Cahill KN; Yu C; Silver H; Niswender K; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Feb; 25(2):570-580. PubMed ID: 36306151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    Lundgren JR; Janus C; Jensen SBK; Juhl CR; Olsen LM; Christensen RM; Svane MS; Bandholm T; Bojsen-Møller KN; Blond MB; Jensen JB; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    N Engl J Med; 2021 May; 384(18):1719-1730. PubMed ID: 33951361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.
    Reidelberger R; Haver A; Chelikani PK; Apenteng B; Perriotte-Olson C; Anders K; Steenson S; Blevins JE
    Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1576-85. PubMed ID: 22510712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
    Kim SH; Abbasi F; Nachmanoff C; Stefanakis K; Kumar A; Kalra B; Savjani G; Mantzoros CS
    Diabetes Obes Metab; 2021 Feb; 23(2):489-498. PubMed ID: 33140542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.
    Zhu H; Zhou L; Wang Q; Cai Q; Yang F; Jin H; Chen Y; Song Y; Zhang C
    Ann Rheum Dis; 2023 Sep; 82(9):1218-1226. PubMed ID: 37258065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
    Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
    Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36.
    Iepsen EW; Lundgren J; Holst JJ; Madsbad S; Torekov SS
    Eur J Endocrinol; 2016 Jun; 174(6):775-84. PubMed ID: 26976129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
    Astrup A; Carraro R; Finer N; Harper A; Kunesova M; Lean ME; Niskanen L; Rasmussen MF; Rissanen A; Rössner S; Savolainen MJ; Van Gaal L;
    Int J Obes (Lond); 2012 Jun; 36(6):843-54. PubMed ID: 21844879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial.
    van Ruiten CC; Ten Kulve JS; van Bloemendaal L; Nieuwdorp M; Veltman DJ; IJzerman RG
    Psychoneuroendocrinology; 2022 Mar; 137():105667. PubMed ID: 35033928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms.
    Kanoski SE; Ong ZY; Fortin SM; Schlessinger ES; Grill HJ
    Diabetes Obes Metab; 2015 Mar; 17(3):285-93. PubMed ID: 25475828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.
    Jensen SBK; Blond MB; Sandsdal RM; Olsen LM; Juhl CR; Lundgren JR; Janus C; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    EClinicalMedicine; 2024 Mar; 69():102475. PubMed ID: 38544798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
    Kaineder K; Birngruber T; Rauter G; Obermüller B; Eichler J; Münzker J; Al-Zoughbi W; Mautner SI; Torekov SS; Hartmann B; Kotzbeck P; Pieber TR
    Int J Obes (Lond); 2017 Aug; 41(8):1263-1270. PubMed ID: 28507313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity.
    Bensignor MO; Kelly AS; Kunin-Batson A; Fox CK; Freese R; Clark J; Rudser KD; Bomberg EM; Ryder J; Gross AC
    Pediatr Obes; 2024 May; 19(5):e13105. PubMed ID: 38339799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.